MGNX DEADLINE NOTICE: ROSEN, A LEADING NATIONAL FIRM, Encourages MacroGenics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 24 Deadline in Securities Class Action - MGNX

Core Viewpoint - Rosen Law Firm is encouraging investors of MacroGenics, Inc. who experienced losses exceeding $100,000 during the specified class period to secure legal counsel before the September 24, 2024 deadline for a securities class action lawsuit [2][3]. Group 1: Class Action Details - The class period for the MacroGenics securities class action is from March 7, 2024, to May 9, 2024, inclusive [2]. - Investors who purchased stock or sold puts during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A class action lawsuit has already been filed, and potential lead plaintiffs must move the court by September 24, 2024 [4]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [5]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company and has recovered hundreds of millions for investors [5]. Group 3: Case Allegations - The lawsuit alleges that during the class period, MacroGenics made false and misleading statements regarding the safety profile of its drug vobramitamab duocarmazine (vobra duo) in a Phase 2 study for resistant prostate cancer [6]. - The misleading statements created a materially false impression about the drug's safety and the overall data from the Phase 2 TAMARACK study, leading to investor damages when the truth was revealed [6].